Biogen, Sanofi and Novartis are all touting new data showing long-term benefits for their respective meds at this year's European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting--and with tough new competition on the way, they may need it.
Last week, the U.S. Patent Trial and Appeal Board took a long-term Gilenya patent out of commission, putting the Novartis multiple sclerosis drug in line for early generic competition.
Novartis is dealing with more regulatory pushback on its MS med Gilenya as the agency said it will update Gilenya's label to reflect cases of serious brain infections linked to the pill.
Pfizer is still king of the CNS hill, bringing in sales that top its Big Pharma rivals. But the company could soon face some competition at the top, as Biogen moves in with promising sales for its multiple sclerosis drugs, according to a report from GlobalData prepared for PMLiVE.
Novartis is looking to expand sales of oral multiple sclerosis therapy Gilenya, which currently trails Biogen Idec pill Tecfidera in the MS arena despite its first-to-market advantage. But it looks like it won't be doing that with a primary progressive MS indication anytime soon.
Novartis' multiple sclerosis drug Gilenya may be able to mitigate a painful side effect of chemotherapy in cancer patients, according to a new preclinical study.
Fresh off winning European backing for broader use--which could prompt more multiple sclerosis patients to switch--Gilenya's ability to protect patients' brains is at center stage at this week's American Academy of Neurology meeting.
The day after showing that two of their respective therapies provided better results with earlier treatments, the companies followed up with analyses of safety and brain volume loss for their oral drugs, both of which have already gained significant market share in treating the disease.
Herewith we bring you our Top 15 Drug Launch Superstars. Some of them will be obvious to anyone who follows the pharma business. They certainly were obvious to us. But choosing the rest was a challenge--one we weren't exactly expecting, based on previous experience. Read the full report >>
Novartis' Gilenya, which a consumer watchdog group last year pegged with safety concerns, is again being called into question after a patient taking the MS drug developed a rare brain infection.